The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Stage

Unattributed | Alive

Total Raised

$5.4M

Last Raised

$5.4M | 6 yrs ago

About Fulgent Pharma

Fulgent Pharma is a stealth biotechnology company.

Fulgent Pharma Headquarter Location

4978 Santa Anita Avenue Suite 205

Temple City, California, 91780,

United States

626-350-0537

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Fulgent Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Fulgent Pharma is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Fulgent Pharma Patents

Fulgent Pharma has filed 1 patent.

The 3 most popular patent topics include:

  • Drug delivery devices
  • Ion channels
  • Mitotic inhibitors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/25/2021

Taxanes, Mitotic inhibitors, Drug delivery devices, Ion channels, Polymers

Application

Application Date

2/25/2021

Grant Date

Title

Related Topics

Taxanes, Mitotic inhibitors, Drug delivery devices, Ion channels, Polymers

Status

Application

Latest Fulgent Pharma News

ANP Technologies in Partnership with Fulgent Pharma Teams with Moffitt Cancer Center to Develop a New Class of Leukemia Therapies

Jan 10, 2020

The Moffitt research team recently discovered that a specific pathway receptor is up-regulated in MDS and AML malignant cells, and in particular the malignant stem cells, thus offering a potentially favorable disease-specific target for therapies. By utilizing a ligand specific for this pathway receptor along with a covalently linked nanoparticle developed by ANP and licensed to Fulgent Pharma, the team was able to show potential for treating this type of leukemia at the stem cell level. “Moffitt takes a team approach when it comes to cancer care and research. Our immunology and hematology teams worked together on this novel therapy. We are taking it to the next level, partnering with ANP/Fulgent Pharma to help accelerate translating this discovery from the laboratory to patients in need,” said Jarett Rieger, Sr. Director, Innovation & Industry Alliances of Moffitt. “With our proprietary nano-delivery and nanotherapeutic technology platform, ANP has successfully developed multiple therapies including nanoencapsulated pactlitaxel, which is currently in clinical and licensed to Fulgent Pharma, as well as a nanoencapsulated antibody cocktail of drugs for the treatment of Ebola infection, which was funded for nonhuman primate testing by the US Department of Defense,” says Dr. Ray Yin, President and CEO of ANP. “The Moffitt collaboration expands our nanotechnology platform and spectrum of drug development, enabling ANP and Fulgent Pharma to develop new targeted therapies to benefit cancer patients.” About Moffitt Cancer Center Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 51 National Cancer Institute-designated Comprehensive Cancer Centers , a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt is a Top 10 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 6,500 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org , and follow the momentum on Facebook , Twitter , Instagram and YouTube . About ANP Technologies, Inc. ANP Technologies, Inc. is a world leader in developing innovative nano-therapeutics. In addition to the novel targeted therapy, ANP has also developed nanoencapsulated chemotherapeutics, antibody therapies, immune-oncology and mRNA-based vaccines. Visit ANPTINC.com for more information. About Fulgent Pharma Fulgent Pharma is a clinical-stage specialty pharmaceutical company developing oncology therapies that leverage a proprietary nano-drug delivery technology. Fulgent Pharma’s pipeline features three unique drug platforms: nanoencapsulated chemotherapy drugs being developed via the 505(b)(2) pathway, novel targeted therapies, and small molecule based immuno-oncology drugs. The Company’s lead asset, FID-007, is a nanoencapsulated paclitaxel with improved drug solubility and efficacy, as well as decreased toxicity, and is currently tested in clinical trials. Fulgent Pharma was founded in 2015 and is headquartered in Temple City, California. Fulgent Pharma was spun off from Fulgent Genetics, Inc., (NASDAQ:FLGT) a comprehensive genetic testing company, in 2016. View source version on businesswire.com: https://www.businesswire.com/news/home/20200110005032/en/ Greg Witham, MS

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.